Myeloid Differentiation Primar
y Response Gene (88) (MYD88) Rabbit anti-Human Polyclonal (aa233-248) Antibody- ￥485
- Genwaybio
- 美国
- GWB-B66568
- 2025年07月12日
- 详见官方网站
- 详见官方网站
- 详见说明书
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原：
详见官方网站
- 亚型：
详见官方网站
- 形态：
冻干粉/浓缩液
- 保存条件：
-20℃
- 克隆性：
多克隆
- 标记物：
详见说明书
- 适应物种：
详见说明书
- 宿主：
详见官方网站
- 应用范围：
详见官方网站
- 浓度：
1mg/ml
- 抗体英文名：
Myeloid Differentiation Primary Response Gene (88) (MYD88) Rabbit anti-Human Polyclonal (aa233-248) Antibody
- 规格：
100ug，200ug，1mg
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验【信息】The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling
-like receptor) signal transduction involves five adaptor proteins. MyD88 (myeloid differentiation primary-response gene 88), MAL (MyD88-adaptor-like protein), TRIF (TIR-domain-containing adaptor protein inducing interferon- (IFN)) and TRAM (TRIF-related adaptor
Phenotypic Analysis of BAT versus WAT Differentiation
BAT for UCP1 protein. Left panels show the DAPI nuclear counterstaining; right panels show the Alexa647 signal of the conjugated secondary antibody. Top: IgG isotype control as primary antibody; bottom: rabbit anti UCP1 primary antibody
as In Vivo Models for Cancer Cell Line Xenografts as Predictors of Compound Response in Patients Challenges with Cell Lines as Models of Human Cancer Tumorgrafts as Improved In Vivo Models
技术资料暂无技术资料 索取技术资料
